I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today.
Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page.

Is Durata's Antibiotic Overpriced? A Twitter Conversation

Sometimes Twitter is just amazing. Last night, I tweeted that The Medicines Company’s oritavancin — a hospital antibiotic I’ve been following since it was owned by Intermune, which divested it in 2005 — had just been approved. (Like several other drugs, including Cubist’s blockbuster Cubicin, it was invented at Eli Lilly then licensed out when Lilly left antibiotics.) Then I got this response about a competiting product, Dalvance from Durata, from infectious disease consultant Peter Bornstein. Among those who responded: Atlas Ventures’ Mike Gladstone, a venture capitalist in the biotech space. .

I have no idea if Bornstein is right about the pricing here. But I’m putting the whole thing here because I want to save it.

@matthewherper Fast on the heels of dalbavancin. I wonder what the price?. I was looking at dalba for a patient. Cost: $3K for 1 dose.

Post Your Comment

Post Your Reply

Forbes writers have the ability to call out member comments they find particularly interesting. Called-out comments are highlighted across the Forbes network. You'll be notified if your comment is called out.